Breaking News, Collaborations & Alliances

GSK, Vir Biotechnology Enter Coronavirus Collaboration

Antibody candidates for SARS-CoV-2 to be accelerated into Phase II trials in the next 3-5 months; GSK to invest $250 million in Vir

By: Contract Pharma

Contract Pharma Staff

GlaxoSmithKline and Vir Biotechnology have signed an agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.   The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks. The companies will leve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters